Disease Stage Heterogeneity
Disease Stage Heterogeneity - Related Videos
08:26
Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
0 Views •
Cited by 5 •
2024
This protocol offers a systematic framework for the establishment of ovarian cancer organoids from different disease stages and addresses the challenges of patient-specific variability to increase yield and enable robust long-term expansion for subsequent applications. It includes detailed steps for tissue processing, seeding, adjusting media requirements, and immunofluorescence staining.
02:10
Generating an Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease
0 Views •
2025
This video demonstrates the development of a pro-inflammatory and degenerative organ culture model for early-stage intervertebral disc (IVD) disease using TNF-α. It outlines the procedure for injecting TNF-α into the intervertebral disc and explains the mechanisms through which TNF-α induces inflammation and degradation of the IVD.
01:22
Heterogeneous Catalysis
0 Views •
2026
Heterogeneous catalysis involves a catalyst in a different phase from the reactants. It is a process where the catalyst and the reactants are in distinct phases, typically solid and gas or liquid.Most heterogeneous catalysts are metals, metal oxides, or acids. The list includes transition metals like iron (Fe), cobalt (Co), nickel (Ni), palladium (Pd), platinum (Pt), chromium (Cr), manganese (Mn), tungsten (W), silver (Ag), and copper (Cu). These metals possess partially vacant d orbitals that...
11:15
HKUST-1 as a Heterogeneous Catalyst for the Synthesis of Vanillin
0 Views •
Cited by 12 •
2016
The conversion of trans-ferulic acid to vanillin was achieved by heterogeneous catalysis. HKUST-1 was employed in this synthesis and the essential step in the catalytic process was the generation of unsaturated metal sites. Thus, when the catalyst was activated under vacuum, full vanillin conversion (yield of 95%) was obtained.
07:54
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
0 Views •
Cited by 27 •
2011
Here we describe a method to quantify molecular heterogeneity in histological sections of tumor material using quantitative immunofluorescence, image analysis, and a statistical measure of heterogeneity. The method is intended for use in clinical biomarker development and analysis.
FAQs
As cancer evolves over time, genetically diverse cell populations are exposed to changing conditions. Clonal selection can favor populations with traits associated with different levels of invasion, metastasis, or treatment response. Consequently, the composition of a tumor may shift, creating clinically meaningful differences between earlier and later disease states.
Similar diagnoses do not guarantee identical progression because variation may occur among patients, between tumors, or across regions within one tumor. Genetically diverse populations and changing microenvironments can produce different patterns of progression, including differences in invasion and metastasis. Recognizing these distinctions helps explain why a shared diagnostic label may not predict identical disease course.
The microenvironment changes as disease develops and interacts with genetically distinct cancer cell populations. These shifting conditions can alter which populations persist or expand, contributing to differences in invasion, metastasis, and response to treatment. This interaction matters because stage-related patterns may reflect both cancer-cell evolution and the local context surrounding those cells.
Researchers can combine pathology, imaging, molecular profiling, and longitudinal sampling to examine heterogeneity from complementary perspectives. Together, these approaches can identify differences among tumors or tumor regions and reveal changes over time. This broader characterization can support risk assessment and help identify clinically important subgroups.
By identifying differences in progression and clinically important tumor subgroups, Disease Stage Heterogeneity analysis can refine risk assessment beyond a broad diagnostic category. The resulting information supports more precise staging and patient stratification, helping distinguish patients or tumor regions with different expected behavior. It can also inform treatment selection when disease characteristics are not uniform.
Longitudinal sampling is useful when researchers need to track disease progression or recurrence rather than characterize a tumor at one time point. Comparing samples across time can reveal changes in cancer cell populations and stage-related features. This temporal view complements pathology, imaging, and molecular profiling and supports closer interpretation of evolving disease behavior.